文献速递肺外科

临床IA期影像纯实性肺腺癌亚肺叶切除指征

Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-05-18

本研究回顾200例手术切除的临床IA期影像纯实性肺腺癌,其中57例(29%)为贴壁为主型腺癌。多因素分析显示最大标准化摄取值(SUVmax)是贴壁为主型腺癌的独立预测因素及预后因素,以SUVmax≤3.3为预测标准。SUVmax>3.3时亚肺叶切除组3年局部区域无复发生存显著劣于肺叶切除组(62.7% vs 82.9%,P=.0281)。

要点

  • 影像纯实性临床IA期肺腺癌中29%为贴壁为主型,5年总生存98.1% vs 76.6%(P=.0012)。
  • SUVmax是贴壁为主型腺癌的独立预测因素(P<.0001),预测标准为SUVmax≤3.3。
  • SUVmax>3.3时亚肺叶切除的3年局部区域无复发生存劣于肺叶切除(62.7% vs 82.9%,P=.0281)。

核心结论

  • SUVmax较高有助于识别临床IA期影像纯实性肺腺癌中即使技术上可行也不应考虑亚肺叶切除的患者。

研究设计与样本

  • 回顾性分析200例手术切除的临床IA期影像纯实性肺腺癌的临床病理资料。
  • 影像纯实性肿瘤定义为无磨玻璃影成分、实性肿瘤比等于1.0的肿瘤。

主要发现

  • 57例(29%)为贴壁为主型腺癌。
  • 临床IA期纯实性腺癌5年总生存83.4%,贴壁为主型与非贴壁为主型分别为98.1% vs 76.6%(P=.0012)。
  • 多因素分析显示SUVmax是贴壁为主型腺癌的独立显著变量(P<.0001),也是显著预后因素(P=.034)。
  • 符合SUVmax≤3.3标准者77例(39%),淋巴管侵犯(P=.0012)、血管侵犯(P<.0001)、淋巴结转移(P=.0007)均较少。
  • SUVmax≤3.3 vs >3.3总生存为91.7% vs 78.6%(P=.0031)。

关键数值与推荐

  • 基于受试者工作特征曲线,贴壁为主型腺癌的预测标准为SUVmax≤3.3。
  • SUVmax≤3.3与>3.3的总生存率分别为91.7%与78.6%(P=.0031)。
  • SUVmax>3.3时亚肺叶切除与肺叶切除的3年局部区域无复发生存分别为62.7%与82.9%(P=.0281)。

临床怎么用

  • 对临床IA期影像纯实性肺腺癌,可参考SUVmax评估贴壁为主型可能性及亚肺叶切除适应证。
  • SUVmax>3.3者即使技术上可行,也应慎重考虑亚肺叶切除。

局限性

  • 回顾性研究,样本量200例,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to identify clinical factors associated with lepidic growth in resected clinical stage IA radiologic pure-solid lung adenocarcinoma for identifying a possible sublobar resection candidate in the population. METHODS: Clinicopathologic data were reviewed for 200 surgically resected clinical stage IA pure-solid lung adenocarcinomas. Radiologic pure-solid tumor was defined as a tumor without a ground-glass opacity component, that is, a consolidation tumor ratio equal to 1.0. Lepidic predominant adenocarcinoma included adenocarcinomas in situ, minimally invasive adenocarcinomas, and lepidic predominant invasive adenocarcinomas. RESULTS: A total of 57 patients (29%) had lepidic predominant adenocarcinoma. The 5-year overall survival of clinical stage IA pure-solid adenocarcinoma was 83.4% and that of lepidic predominant adenocarcinoma and nonlepidic predominant adenocarcinoma was 98.1% versus 76.6% (P = .0012). A multivariate analysis revealed that maximum standardized uptake value was an independently significant variable of lepidic predominant adenocarcinoma (P < .0001) and a significant prognostic factor (P = .034). The predictive criterion of lepidic predominant adenocarcinoma was maximum standardized uptake value 3.3 or less based on a receiver operating characteristic curve, and 77 patients (39%) who met this criterion showed less pathologic invasiveness regarding lymphatic (P = .0012) and vascular (P < .0001) invasions, nodal metastasis (P = .0007), and better overall survival than those who did not (maximum standardized uptake value ≤3.3 vs >3.3 rates being 91.7% vs 78.6%, P = .0031). Moreover, the 3-year locoregional recurrence-free survival of the sublobar resection arm was significantly worse than that of the lobectomy arm when the tumor showed maximum standardized uptake value greater than 3.3 (62.7% vs 82.9%, P = .0281). CONCLUSIONS: Higher maximum standardized uptake value may be useful for identifying patients with clinical stage IA radiologic pure-solid lung adenocarcinoma in whom sublobar resection should not be considered, even if technically feasible.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hattori A, Matsunaga T, Takamochi K, et al. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017. PMID: 28629842. doi:10.1016/j.jtcvs.2017.03.153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。